 YARDLEY, Pa., July 29, 2020 GLOBE NEWSWIRE -- Optinose NASDAQ:OPTN, a pharmaceutical company focused on patients treated by ear, nose and throat ENT and allergy specialists, today announced its Board of Directors has named Catherine E. Owen as a new director. Catherine currently serves as Senior Vice President, Major Markets at Bristol-Myers Squibb, overseeing commercial operations for the business in 18 countries including Japan, Germany, France, and others across Europe. She joined BMS in 2019 from Johnson Johnson, where she served most recently as President of Janssen Immunology North America, which launched new products in Crohns disease and psoriasis and led the development of JJs biosimilars strategy. Prior to leading Immunology, she was the President of the Infectious Diseases business in the US, responsible for the HIV, RSV, Flu, and Hepatitis B pipeline. Prior to that she worked in various functions and businesses at JJ and led the launches of multiple products in both Europe and the US. Catherine began her career in the pharmaceutical industry in 1992 at AstraZeneca in London as a production support pharmacist. Catherine earned her Bachelor of Science degree in pharmacy from the University of Manchester and completed her registered pharmacy degree and was a member of the Royal Pharmaceutical Society, MRPhs. In 2019, in recognition of her efforts as a developer of talent, the Healthcare Businesswomens Association HBA named Owen an HBA Luminary.We are pleased to welcome Catherine to the Optinose Board of Directors, stated Joe Scodari, Chairman of the Optinose Board of Directors. Her global executive-level experience in the pharmaceuticals industry, along with her marketing, sales, and strategy acumen support our belief that she is an exceptional candidate to join our Board of Directors.About Optinose Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat ENT and allergy specialists. To learn more, please visit or follow us on Twitter and LinkedIn.Optinose Investor Contact Jonathan Neely 267.521.0531 